<DOC>
	<DOCNO>NCT02058108</DOCNO>
	<brief_summary>The purpose study assess efficacy safety telbivudine dose 20 mg/kg maximum 600 mg q.d . compensate pediatric HBeAg-positive negative CHB patient age 2 &lt; 18 year indication antiviral CHB treatment . This study part commitment pediatric development plan telbivudine Europe US .</brief_summary>
	<brief_title>Study Efficacy Safety , Tolerability Pharmacokinetics Telbivudine Children Adolescents With Compensated Chronic Hepatitis B Virus Infection</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Telbivudine</mesh_term>
	<criteria>Clinical history compatible compensate chronic hepatitis B Documented compensate chronic hepatitis B define follow : oPositive serum HBsAg screen least one documentation HBsAg positive least 6 month prior screen oFor HBeAg positive patient screen , significant biologic and/or histologic sign disease activity follow EASL guideline recommendation CHB pediatric patient ( serum HBV DNA level ≥ 5 log10 copies/mL ( 20 000 IU/mL ) ( COBAS Taqman® ) screening ; serum ALT ≥ 1.5×ULN &lt; 10×ULN ( pediatric ULN ) two time screening period within 6 month prior screen oFor HBeAg negative patient screen , significant biologic and/or histologic sign disease activity follow EASL guideline recommendation CHB pediatric patient ( serum HBV DNA level ≥ 4 log10 copies/mL ( 2 000 IU/mL ) ( COBAS Taqman® ) screen ) ; serum ALT ≥ 1.0 ×ULN &lt; 10×ULN ( pediatric ULN ) two time screening period within 12 month prior screen ) Patients acute chronic infection HCV , HDV , HIV , acute infection HAV , HEV , CMV , EBV , HSV . Patient receive treatment interferon immunomodulatory agent within last 12 month prior screen nucleoside nucleotide drug antiCHB treatment ( approved investigational ) time screen Patient medical condition require frequent use systemic acyclovir famciclovir , systemic corticosteroid , potentially hepatotoxic drug nephrotoxic drug chemotherapy Patient one additional know primary secondary cause liver disease , CHB ; decompensated liver disease ; Liver transplant recipient organ bone marrow transplant recipient . History acute chronic medical condition ( opinion investigator would make patient unsuitable inclusion study . Patient history myopathy , myositis , persistent muscle weakness persistent high serum CK level ( ≥7×ULN ) , muscular disease Patient receive drug potentially associate myopathy within 3 month prior screen Any clinical significant disease , condition abnormality , unrelated HBV infection screening , assess investigator</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Chronic hepatitis B , pediatrics , antiviral treatment , telbivudine</keyword>
</DOC>